摘要
3例重症肝病合并感染患者(均为男性,年龄分别为40、68、50岁)接受碳青霉烯类、利奈唑胺及氟康唑联合治疗,期间未出现明显血象变化。因疗效不佳换用哌拉西林钠他唑巴坦钠4.5 g,8 h/次静脉滴注。其中例1于换用哌拉西林钠他唑巴坦钠11 d后出现贫血及血小板计数下降;例2、例3分别于换用哌拉西林钠他唑巴坦钠4、7 d后出现贫血加重及血小板计数下降。3例患者分别在停用哌拉西林钠他唑巴坦钠后31、21、7 d,血红蛋白及血小板计数明显恢复。
Three patients with severe liver diseases and infections （all males, aged 40, 68, and 50, respectively） were treated with carbapenem, linezolid, and fluconazole. No obvious change of hemogram result was found during the period of drugs use. The therapy was replaced with an Ⅳ infusion of piperacillin sodium and tazobactam sodium 4.5 g every 8 hours due to poor efficacy. Patient 1 devdoped platelet count decrease and anemia after the treatment with piperacillin sodium and tazobactam sodium for 11 days. Patients 2 and 3 developed platelet count decrease and exacerbation of anemia after the treatment with piperacillin sodium and tazobactam sodium for 4 and 7 days, respectively. Three patients＇ hemoglobin levels and platelet counts apparently recovered on days 31, 21, and 7 after the discontinuation of medication, respectively.
出处
《药物不良反应杂志》
CSCD
2013年第3期170-171,共2页
Adverse Drug Reactions Journal
基金
国家十二五传染病重大专项(2012ZX1002-008-05)
北京市科技计划项目(H010210110129
Z111107058811067)
北京市高层次卫生人才学科带头人项目(2011-2-19)
佑安肝病艾滋病基金科研课题(BJYAH-2011-053)
作者简介
通信作者：丁惠国，Email：dinghuiguo@medmail．com.cn
